Last reviewed · How we verify
PLB1004
PLB1004 is a small molecule inhibitor targeting a specific molecular pathway in cancer or immune-related disease.
At a glance
| Generic name | PLB1004 |
|---|---|
| Also known as | Andamertinib |
| Sponsor | Avistone Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information, PLB1004's exact target and mode of action cannot be reliably specified. As a Phase 3 asset from Avistone Biotechnology, it is likely a targeted therapeutic, but the specific molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.
Approved indications
Common side effects
Key clinical trials
- Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations (PHASE2)
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (PHASE3)
- Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive (PHASE1, PHASE2)
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (PHASE1, PHASE2)
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure (PHASE3)
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. (PHASE2)
- A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLB1004 CI brief — competitive landscape report
- PLB1004 updates RSS · CI watch RSS
- Avistone Biotechnology Co., Ltd. portfolio CI